Phone: 614/488-2118
Fax: 614/488-2647
1335 Dublin Rd., Suite 124A
Columbus, OH 43215
Member Sign in
HOME
MEMBERS
CANCER RESOURCES
ABOUT
EVENTS
EMPLOYMENT
CONTACT
Protocol Database
User Profile
Index of Forms
Ohio Partners for Cancer Control
Consortium Members
Treatment Sites & Physicians
Community Based Research Nurses
NCORP Videos
Our Team
Donate
HOME
MEMBERS
Protocol Database
User Profile
Index of Forms
CANCER RESOURCES
Ohio Partners for Cancer Control
ABOUT
Consortium Members
Treatment Sites & Physicians
Community Based Research Nurses
NCORP Videos
EVENTS
EMPLOYMENT
CONTACT
Our Team
Donate
Enter your search term
Protocol Categories
View All Protocols
PROTOCOL CREDENTIALS
Brain
Breast
CA Control
CCDR
Gastrointestinal
Genitourinary
GYN
Head and Neck
Hematology
Lung
Lymphoma
Melanoma / Skin-Other
Multiple Disease Sites
Observational
RT
Sarcoma
Unknown Primary
DCP
Hematology
Alliance A041702
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
ECOG EA9161
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
ECOG EAA173
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
ECOG EAA181
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
ECOG NHLBI-MDS
The National Myelodysplastic Syndromes (MDS) Study
NCI COVID-19
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
OSU 2010-C0126 Buckeye Surveillance
Buckeye Surveillance, Contact, and Research for MGUS, Myeloma and Amyloidosis
SWOG S1712
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
SWOG S1803
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)